Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib; Cisplatin; Gemcitabine

Criteria

Inclusion Criteria:

• Histologically- or cytologically-confirmed diagnosis of squamous NSCLC Stage IIIB with malignant effusion (fluid cytology demonstrating malignant cells required), Stage IV, or recurrent disease after definitive local therapy

• Candidate for primary treatment with cisplatin and gemcitabine

• Presence of measurable disease by RECIST

• Adequate organ function as defined by the following criteria: ECOG performance status of 0 or 1

Exclusion Criteria:

• Prior systemic treatment for Stage IIIB (with malignant effusion) or Stage IV NSCLC.

• One or more lung lesions with cavitation, or any lesion invading or abutting a major blood vessel as assessed by CT or MRI.

• History of hemoptysis > ½ tsp (2.5 ml) of blood per day for a day or more within 1 week of study treatment, or Grade 3 or 4 hemoptysis within 4 weeks of study treatment

• NCI CTCAE Grade 3 hemorrhage from any cause within 4 weeks of study treatment

• Preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart.

• Untreated brain metastases.

• Need for therapeutic anticoagulation, regular use of aspirin (> 325 mg/day), NSAID or other medications known to inhibit platelet function.